EICHOR
● Not Yet Recruiting
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
Condition: Ulcerative Colitis in Remission · Sponsor: Assistance Publique Hopitaux De Marseille
About this study
This phase IV, multicenter, open-label randomized controlled trial will evaluate whether a JAK inhibitor discontinuation strategy is superior to standard maintenance therapy in adult patients with ulcerative colitis who are in sustained deep remission. A total of 224 patients treated with tofacitinib, upadacitinib, or filgotinib will be randomized to either treatment withdrawal or continuation of maintenance therapy and followed for 104 weeks. The primary objective is to compare safety, efficacy, and patient satisfaction at Week 52, while secondary objectives include assessment of remission maintenance, quality of life, treatment exposure, endoscopic outcomes, and relapse rates
This description comes directly from the study's public registry record.
Talk to the study team
Amandine ROLLAND-BRUN · +33 04 91 38 12 45 · amandine.rolland@ap-hm.fr
Always discuss trial participation with your own doctor first.
Locations (22)
| CHU Amiens-Picardie | Amiens, France | — |
| Centre Hospitalier d'Avignon | Avignon, France | — |
| CHRU Besançon | Besançon, France | — |
| CHU Bordeaux | Bordeaux, France | — |
| CHU Clermont Ferrand | Clermont-Ferrand, France | — |
| Chu Lille | Lille, France | — |
| HCL | Lyon, France | — |
| AP-HM hopital Nord | Marseille, France | — |
| CHU Montpellier | Montpellier, France | — |
| CHRU Nancy | Nancy, France | — |
| CHU Nantes | Nantes, France | — |
| CHU Nice | Nice, France | — |
+ 10 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.